Organization (Industry)
GILEAD SCIENCES, INC.
ClinicalTrials.gov lists GILEAD SCIENCES, INC. as lead sponsor of 694 trials, counting the companies grouped under it. GILEAD SCIENCES, INC. itself has 284 active development programs and 167 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 36 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 41 in 2026 and about 43 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers GILEAD SCIENCES, INC. and 1 company grouped under it: 694 lead-sponsored trials (694 its own, 0 in the grouped companies) and 12 legal-entity registrations (11 its own, 1 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| GILEAD SCIENCES IRELAND UNLIMITED COMPANY | 0 | 1 |
Disease areas (273)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 193 |
| Hepatitis C | 176 |
| Acquired Immunodeficiency Syndrome | 91 |
| Hepatitis B | 81 |
| Hepatitis C, Chronic | 55 |
Showing 5 of 273 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 36 |
| 2025 | 41 |
| 2024 | 43 |
| 2023 | 45 |
| 2022 | 42 |
| 2021 | 60 |
| 2020 | 48 |
| 2019 | 49 |
| 2018 | 47 |
| 2017 | 59 |
Showing 10 of 29 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 35 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 571 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (284)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sacituzumab Govitecan | Breast Neoplasms | Phase 3 | 13 |
| Sacituzumab Govitecan | Triple Negative Breast Neoplasms | Phase 3 | 9 |
| NAB paclitaxel | Breast Neoplasms | Phase 3 | 5 |
| (nab)-paclitaxel | Breast Neoplasms | Phase 3 | 5 |
| Sacituzumab Govitecan | Carcinoma, Non-Small-Cell Lung | Phase 3 | 4 |
Showing 5 of 284 active programs.
Approved assets (167)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ribavirin | 69 |
| Fumarate, Tenofovir Disoproxil | 41 |
| Idelalisib | 32 |
| B/F/TAF | 27 |
| Sofosbuvir | 19 |
Showing 5 of 167 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 42% hit target (n=170) | 52% on time (n=174) |
Journals published in (468)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 74 |
| The New England journal of medicine | 72 |
| PloS one | 60 |
| Journal of acquired immune deficiency syndromes (1999) | 55 |
| AIDS (London, England) | 54 |
Showing 5 of 468 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,391 | 280 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 29,443,000,000 | 8,510,000,000 | 5,799,000,000 |
| 2024 | 28,754,000,000 | 480,000,000 | 5,907,000,000 |
| 2023 | 27,116,000,000 | 5,665,000,000 | 5,718,000,000 |
| 2022 | 27,281,000,000 | 4,592,000,000 | 4,977,000,000 |
| 2021 | 27,305,000,000 | 6,225,000,000 | 4,601,000,000 |
| 2020 | 24,689,000,000 | 123,000,000 | 4,927,000,000 |
| 2019 | 22,449,000,000 | 5,386,000,000 | 4,055,000,000 |
| 2018 | 22,127,000,000 | 5,455,000,000 | 3,920,000,000 |
| 2017 | 26,107,000,000 | 4,628,000,000 | 3,734,000,000 |
| 2016 | 30,390,000,000 | 13,501,000,000 | 5,098,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (26)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-20 | Debt financing | 3,000,000,000 | Sec extracted |
| 2026-05-18 | Debt financing | 2,999,495,000 | Edgar offerings |
| 2026-05-14 | Other financing | not disclosed | Edgar offerings |
| 2026-04-28 | Other financing | not disclosed | Sec extracted |
| 2026-02-22 | Other financing | not disclosed | Sec extracted |
Showing 5 of 26 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 29 |
FDA recalls (7)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 | Class I | 2024-09-19 |
| Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 | Class I | 2021-12-03 |
| Emtriva (emtricitabine) Oral Solution, 10 mg/mL, 170 mL bottles, Rx only, Manufactured for Gilead Sciences, Inc., Foster City, CA NDC 61958-0602-1 Gilead Sciences, Inc. Foster City, CA 94404. | Class II | 2014-10-01 |
| Truvada (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablets, 30 count bottles, Rx only, Manufactured for Gilead Sciences, Inc. Foster City, CA 94404, NDC 61958-0701-1 | Class III | 2014-09-30 |
| Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) Tablets, 30 Tablet Bottles, Rx only. Manufactured for: Bristol-Myers Squibb & Gilead Sciences, LLC, Foster City, CA 94404. Made in Ireland. NDC 15584-0101-1. Manufactured for: Bristol-Myers-Squibb & Gilead Sciences, LLC, Foster City, CA 94404 Made in Ireland | Class III | 2014-02-19 |
Showing 5 of 7 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 10 | 2024-11-12 |
Manufacturing and distribution sites (6)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Gilead Sciences, Inc. | La Verne, US | FDA, Health Canada | |
| Gilead Sciences, Inc. | Foster City, US | FDA, Health Canada | |
| Gilead Sciences, Inc. | Oceanside, US | FDA | |
| Gilead Sciences Inc. | San Dimas, US | Health Canada | |
| Gilead Sciences Inc. | San Dimas, US | Health Canada |
Showing 5 of 6 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (329)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 43 |
| GSK plc | Co sponsors trial with | 19 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 19 |
| Lakefront Biotherapeutics NV | Co sponsors trial with | 15 |
| French National Agency for Research on AIDS and Viral Hepatitis | Co sponsors trial with | 11 |
Showing 5 of 329 relationships.
Latest dated events (2,647)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,647 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| GILEAD SCIENCES INC | Certificate of compliance | Terminated |
Biomarker capability evidence (3,434)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACSBG1 | Trial sponsor | Named in trial inclusion criteria |
| ACSBG1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 3,434 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: fda warning letters, fda untitled letters, and biomarkers this organization publishes on.